Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00633529 · ClinicalTrials.gov registry record · Phase 1
Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC
A Phase 1 study, sponsored by EMD Serono.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT00633529 is a Phase 1 study that has completed, run by EMD Serono. The registered enrollment target is 36 participants.
The verdict
NCT00633529, a Phase 1 study, has completed, sponsored by EMD Serono.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
To evaluate the safety of the proposed Phase II dosage of the investigational drug IMO 2055 when combined with erlotinib and bevacizumab in patients with previously treated advanced NSCLC.
Interventions
- DRUG IMO-2055
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2007-11 |
| Est. Completion | 2011-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00633529
The ClinicalTrials.gov registry entry for NCT00633529 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IMO-2055 is the first listed.
NCT00633529 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00633529 about?
NCT00633529 is a clinical study titled "Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC". To evaluate the safety of the proposed Phase II dosage of the investigational drug IMO 2055 when combined with erlotinib and bevacizumab in patients with previously treated advanced NSCLC.
What is the current status of trial NCT00633529?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2007-11. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00633529?
The interventions under investigation include: IMO-2055 (DRUG).
Who is sponsoring clinical trial NCT00633529?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.